HUTCHMED (China) Ltd at Bank of America Global Healthcare Conference Transcript
Hey, everyone. Good afternoon, and welcome to day 2 of the 2023 BofA Healthcare Conference. Thanks for joining the session with HUTCHMED. My name is Alec Stranahan. I'm Vice President and senior biotech analyst covering HUTCHMED here at BofA. And I'm pleased to be joined by Mark -- Mike, who's the CMO of HUTCHMED. And I think Mike's going to give some prepared remarks to set the stage, and then we'll jump into Q&A. So over to you Mike.
()- -
Yes. Thank you, Alec. Yes, it's a great pleasure to be here. And I just want to have a few words about HUTCHMED, is a biotech company based -- headquartered in Hong Kong. It's been for 20 years, and we have three products already marketed in China, savolitinib, fruquintinib and surufatinib. And we also have a full integrated discovery, development and the commercial pipeline in China. In -- extra China side,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |